Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YPN-007
- Development stage
- Preclinical
- Lead developer
- Yungjin Pharm
- Modality
- Small Molecules
- Administration
- Oral, Injection
01
Overview
YPN-007 is a small molecule drug candidate currently in the discovery stage of development by Yungjin Pharmaceutical. It is being investigated for applications in immuno-oncology. As a New Chemical Entity (NCE) within Yungjin's internal pipeline, YPN-007 is designed to modulate the immune response against cancer cells. While the specific molecular target has not been publicly disclosed, the asset represents part of the company's strategic focus on developing novel oncology therapeutics through its internal R&D programs.
- Other names
- YPN-007-Yangjin-Immuno-oncologyYPN007-Yangjin-Immuno-oncologyYPN 007-Yangjin-Immuno-oncology
Beyond the preview
Go deeper on YPN-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YPN-007.